HGCO19 vaccine candidate: Gennova starts enrolment for Phase 1/2 human clinical trials
The DBT said it has approved additional funding towards clinical studies of India's first of its kind' mRNA-based COVID-19 vaccine, HGCO19, developed by Pune-based biotechnology company Gennova Biopharmaceuticals Ltd.
Source: The Economic Times Healthcare and Biotech News - Category: Pharmaceuticals Source Type: news
More News: Biotechnology | Clinical Trials | COVID-19 | Funding | India Health | Pharmaceuticals | Study | Vaccines